Enabling the Nervous System to Repair Itself

We create innovative treatments for nervous system damage due to injury or disease.

NervGen Pharma

NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company creating innovative treatments that enable the nervous system to repair itself following damage. NervGen’s lead drug candidate, NVG-291 is currently in a Phase 1 clinical trial. The company’s initial target indications are Alzheimer’s disease, spinal cord injury and multiple sclerosis.

Stay Connected

Subscribe to our mailing list to stay up to date

The NervGen Story

In this inspiring and heartfelt video, Dr. Jerry Silver, Professor of Neurosciences, Case Western Reserve University, shares his journey and how the research carried out in his lab led to the formation of NervGen.

The video highlights how NervGen is developing Dr. Silver’s foundational discoveries into a disruptive technology that is aimed at changing the paradigm of how nervous system damage will be treated.

The Latest

News Release

July 28, 2022

The independent peer-reviewed study showed improved memory as well as motor and sensory functions in rodents when treatment with NVG-291-R began 7 days after stroke onset


May 31, 2022

Health Europa features NervGen Pharma and the potential of NVG-291 to treat Alzheimer’s.


February 11, 2022

Interview with Paul Brennan, NervGen President & CEO (Interview at 29:22 in video)